Galectin-3, advanced glycated end-products serum levels, endothelial function and cardiac hemo¬dynamics in post infarction heart failure patients with reduced and preserved ejection fraction.
DOI:
https://doi.org/10.26641/2307-0404.2018.2(part1).129519Keywords:
postinfarction chronic heart failure, galectin-3, AGEs, endothelial dysfunction, cardiac hemodynamicsAbstract
Epidemiological studies have reported that the rate of signs and symptoms of heart failure after myocardial infarction is approximately 25%. In addition, approximately 40% of myocardial infarctions are accompanied by left ventricular systolic dysfunction. Aim.. Aim of the study is to evaluate serum levels of galactin-3, AGEs and endothelial function, cardiac hemodynamics in post infarction chronic heart failure patients with different ejection fraction. Materials and methods. All patients are divided into two main groups according to ejection fraction:1st group-20 patients with chronic heart failure with preserved ejection fraction, 2nd group-15 patients with chronic heart failure and reduced ejection fraction. Standard laboratory blood tests for erythrocyte sedimentation rate, haematological parameters, lipid profile, glucose, renal function, echocardiographic examination, endothelial function determine were performed for all patients. AGEs and galectin-3 serum levels were determined. Results. Patients with chronic heart failure and reduced ejection fraction and myocardial infarction in anamnesis had significantly increased left ventricle diastolic volume, left ventricle systolic volume,left ventricle diastolic dimension and left ventricle systolic dimension (p<0.05).AGEs serum level mildly increased in both groups.Galectin-3 level was significantly higher in pts with chronic heart failure and reduced ejection fraction(p < 0.05)and was correlated with age(R=0.74, p<0.05), left ventricle end diastolic volume (R=0.57, p<0.05), left ventricle end diastolic dimension (R=0.48, p<0.05), triglycerides level (R=0.45, p < 0.05). Most of the patients with chronic heart failure with myocardial infarction in anamnesis had endothelial dysfunction, the FMD% level was significantly higher in patients with preserved ejection fraction(p<0.05). Conclusions. Patients with chronic heart failure and reduced ejection fraction are characterized by significantly higher levels of galectin-3, endothelial dysfunction frequency, cardiac hemodynamics abnormalities.
References
Hartog JW, Voors AA, Bakker SJ, et al. Advanced glycation endproducts (AGEs) and heart failure: pathophysiology and clinicalimplications. Eur J Heart Fail. 2007;9:1146-55. doi: 10.1016/j.ejheart.2007.09.009
Albert NM, Lewis C. Recognizing and managing asymptomatic left ventricular dysfunction: after myocardial infarction. Crit CareNurse. 2008;28:20-37.
Thijssen DHJ, Black MA, Pyke K, Padilla J, Atkinson GA, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow mediated dilation (fmd) in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011;300:H2–H12. doi: 10.1152/ajpheart.00471.2010
Lindsey JB, de Lemos JA, Cipollone F, et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care. 2009;32:1218-20. doi: 10.2337/dc09-0053
Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep 2008;60:119-26.
Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehs104
Jiang JX, Chen X, Hsu DK, et al. Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol. 2012;302:G439-46. doi: 10.1152/ajpgi.00257.2011
Møller JE, Whalley GA, Dini FL, et al. Independentprognostic importance of a restrictive left ventri-cularfilling pattern after myocardial infarction: an individual patientmeta-analysis: Meta-Analysis Research Group in Echocardiographyacute myocardial infarction. Circulation. 2008;117:2591-8. doi: 10.1161/CIRCULATIONAHA.107.738625. Epub 2008 May 12.
Kuryata OV, Abdunaser A Zabida. Effect of L-Arginine on the Serum Level of Advanced Glycation End Products in Patients with Post Infarction Chronic Heart Failure.Journal of Nutritional Therapeutics. 2017;6(2):43-50.
Kuryata O, Sirenko O. Endothelial function, insulin resistance, serum adiponectin level in rheumatoid arthritis females with renal dysfunction and its dynamics with L-arginine aspartate supplementation. Prensa Med Argent. 2017;103:6.
Kuryata O, Sirenko O. The inter relation of insulin resistance, serum adiponectin level in rheumatoid arthritis hypertensive females with subclinical atherosclerosis and its dynamics with the endothelial dysfunction correction. Orthopaedic Surgery and Traumatology. 2017;1(5):162-73.
Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann NY Acad Sci. 2010;1183:158-82. doi: 10.1111/j.1749-6632.2009.05131.x
Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032-7. doi: 10.1136/thx.2008.095588
Blair JE, Manuchehry A, Chana A, et al. Prognostic markers in heart failure – congestion, neurohormones, and the cardiorenal syndrome. Acute Card Care. 2007;9:207-13. https://doi.org/10.1080/17482940701606913
Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, anovel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323-8.
Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids. 2010;19. doi: 10.1007/s10741-010-9225-z
Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: new roles for soluble RAGE. Eur J Heart Fail. 2010;12:1092-100. doi: 10.1093/eurjhf/hfq117
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2018 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
